0.50Open0.30Pre Close508 Volume317 Open Interest5.00Strike Price32.53KTurnover112.03%IV8.32%PremiumMay 16, 2025Expiry Date0.17Intrinsic Value100Multiplier22DDays to Expiry0.43Extrinsic Value100Contract SizeAmericanOptions Type0.6057Delta0.2713Gamma7.95Leverage Ratio-0.0129Theta0.0015Rho4.82Eff Leverage0.0049Vega
Pulmonx Stock Discussion
Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024
Pulmonx (Nasdaq: LUNG) presented clinical data from two significant studies at the European Respiratory Society Congress 2024. The AeriSeal® CONVERT trial showed that 77.6% of patients with collateral ventilation (CV+) successfully converted to CV- status after treatment with the AeriSeal System...
No comment yet